

IN THE SPECIFICATION:

At page 5, line 14, please delete the section that corresponds to the following replacement section:

--R₁-Val-His-Phe-Phe-Lys-Asn-Ile-R₂ (SEQ ID NO:2)--

At page 5, line 23, please delete the section that corresponds to the following replacement section:

--Examples of said peptides are selected from (SEQ ID NOS:3 to 13):--

At page 9, line 15, please delete the section that corresponds to the following replacement section:

--Fig 11[[a]]A shows free--

At page 9, line 19, please delete the section that corresponds to the following replacement section:

--Fig 11[[b]]B shows free--

At page 9, line 24, please delete the section that corresponds to the following replacement section:

--Fig 11[[c]]C shows free--

At page 9, line 28, please delete the section that corresponds to the following replacement section:

--Fig 11[[d]]D shows free--

At page 12, line 14, please delete the section that corresponds to the following replacement section:

--R₁-Val-His-Phe-Phe-Lys-Asn-Ile-R₂ (SEQ ID NO:2)--

At page 12, line 31, please delete the section that corresponds to the following replacement section:

--additions or deletions can be made to the sequence R₁-Val-His-Phe-Phe-Lys-Asn-Ile-R₂
(SEQ ID NO:2),--

At page 13, line 12, please delete the section that corresponds to the following replacement section:

--~~SEQ ID NO:1~~ SEQ ID NO:1. The length of said peptide can range from a single amino acid--

At page 13, line 17, please delete the section that corresponds to the following replacement section:

--~~SEQ ID NO:1~~ SEQ ID NO:1. The length of said peptide can range from a--

At page 13, lines 20-21, please delete the section that corresponds to the following replacement section:

--Val-His-Phe-Phe-Lys-Asn-Ile (SEQ ID NO:2), or modifications thereof,--

At page 15, line 1, please delete the section that corresponds to the following replacement section:

--~~SEQ ID NO:1~~ SEQ ID NO:14 (amino acids 61 to 106 of SEQ ID NO:1)--

At page 15, line 7, please delete the section that corresponds to the following replacement section:

--Examples of peptides are selected from the group consisting of (SEQ ID NOS:5, 4, 6, 3, 7 and 8, respectively):--

At page 15, line 25, please delete the section that corresponds to the following replacement section:

--R₁-Val-His-Phe-Phe-Lys-Asn-Ile-R₂ (SEQ ID NO:2)--

At page 16, line 1, please delete the section that corresponds to the following replacement section:

--Examples of peptides are selected from (SEQ ID NOS:9 to 13):--

At page 20, lines 21-23, please delete the section that corresponds to the following replacement section:

--IgG was purified from concentrated CSF of patients with acute MS by protein A-Sepharose (Pharmacia PHARMACIATM) affinity chromatography as previously described--

At page 20, lines 29-30, please delete the section that corresponds to the following replacement section:

--Purified MBP was coupled to CNBr-activated Sepharose 4B (Pharmacia PHARMACIATM) according to the manufacturer's instructions.--

At page 35, lines 11-12, please delete the section that corresponds to the following replacement section:

--One of these patients (Figure 11[[a]]A) received--

At page 35, line 24, please delete the section that corresponds to the following replacement section:

--attack: four daily injections (Figure 11[[b]]B: it#1, it#2, it#3, it#4) and a fifth injection--

At page 36, line 2, please delete the section that corresponds to the following replacement section:

--relapses. Figure 11[[c]]C illustrates the anti-MBP profile of a patient with acute--

At page 36, line 13, please delete the section that corresponds to the following replacement section:

-- injection (Figure 11[[d]]D: it#1, it#2, it#3, it#4) and 10 days after the first injection--